Archives
-
Resveratrol, SIRT1, and Mitochondrial Neuroprotection
2026-10-07
A source-grounded overview of how resveratrol was studied in a prion-related neuronal cell model, with emphasis on SIRT1, PGC-1α–TFAM signaling, mitochondrial dysfunction, apoptosis, evidence strength, and translational limitations.
-
Separating Growth Arrest from Cell Death in Cancer Assays
2026-10-07
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability to clarify how anticancer drugs affect proliferation and cell death. Its central contribution is an interpretive framework showing that most agents influence both processes, but with different magnitudes and timing, improving how in vitro drug-response data are read.
-
MCL-1 Dependence in Breast Cancer: Study Findings
2026-10-06
Campbell and colleagues show that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic function, rather than because of an essential non-apoptotic role. Genetic loss and pharmacological inhibition both restricted tumor growth, with the effects requiring the pro-apoptotic effectors BAX and BAK and extending to breast cancer stem cell activity.
-
RSL3 and GPX4 Inhibition in Ferroptosis Research
2026-10-06
A source-grounded overview of RSL3 as a GPX4 inhibitor, covering ferroptosis biology, conceptual applications, published evidence, assay interpretation, and the limits of supplier-reported cancer findings.
-
ER-Targeted EISA Peptides in Cancer Cell Fate
2026-10-05
The reference study develops an alkaline-phosphatase-responsive peptide that combines enzyme-instructed self-assembly with endoplasmic-reticulum targeting through a p-toluenesulfonamide group. In the reported cellular models, this design promoted ER stress and selective apoptosis or necroptosis in cancer cells, while lowering the apparent concentration threshold for activity relative to non-targeted intracellular self-assembly.
-
Prion-Based Mutagenesis and Rapid Adaptation
2026-10-05
A 2026 Cell study reports that prion-like protein self-assembly can act as a heritable, reversible switch for mutagenesis in yeast, reshaping adaptation under strong selective pressure. Its cross-system evidence connects protein-state inheritance with genome stability, stress resilience, and drug resistance while highlighting important limits on translating yeast findings to cancer or clinical biology.
-
Birinapant and Apoptosis: Evidence, Context and Limits
2026-10-04
Birinapant (TL32711) is a SMAC mimetic IAP antagonist investigated as a tool for studying apoptosis, TNF signaling and TRAIL responsiveness. This overview compares the supplier-described mechanism with published colorectal cancer findings on MDM1, p53 and chemoradiotherapy, while separating direct evidence from future research hypotheses.
-
KN-62 and Calcium Signaling: Evidence and Limits
2026-10-03
KN-62 is commonly used as a CaMKII-focused research tool, but the supplied evidence does not establish broad pathway selectivity or therapeutic utility. A 2024 glioblastoma study of the distinct compound NNC-55-0396 provides useful context for calcium-dependent stress signaling while underscoring why findings cannot be transferred directly to KN-62.
-
GSK3 Inhibition as Host-Directed TB Therapy
2026-10-02
A 2024 iScience study identifies glycogen synthase kinase 3 as a host pathway that supports intracellular Mycobacterium tuberculosis growth. By combining pharmacological screening with CRISPR knockout, RNA interference, apoptosis analysis, and phospho-proteomics, the work establishes GSK3 inhibition as a mechanistically supported host-directed strategy rather than a conventional antibacterial approach.
-
Sulforaphane, ROS, and NLRP3 in Colitis
2026-10-01
A 2024 Biomedicine & Pharmacotherapy study used DSS-induced mouse colitis and RAW264.7 macrophage experiments to connect sulforaphane-mediated ROS reduction with suppression of NLRP3 inflammasome signaling. The findings support a redox-sensitive mechanism for intestinal inflammation while leaving direct target engagement and clinical efficacy unresolved.
-
Thymoquinone and Doxorubicin Cardiotoxicity
2026-10-01
A 2025 mouse study found that thymoquinone reduced doxorubicin-associated cardiac injury while improving redox balance, mitochondrial morphology, and ferroptosis-related molecular markers. Its central mechanistic contribution is the proposal that Nrf2/HO-1 pathway activation links thymoquinone treatment to reduced oxidative stress and iron-dependent cardiomyocyte death.
-
Sulforaphane: From Redox Signal to Causal Assay
2026-09-30
Sulforaphane research is strongest when redox, inflammasome, cell-cycle, and apoptosis endpoints are interpreted as a causal sequence rather than isolated readouts. This guide develops an orthogonal assay strategy grounded in colitis findings and cancer chemoprevention applications.
-
NHE1, Olfr2, and Calcium-Driven Atherosclerosis
2026-09-30
Wang and colleagues identify macrophage NHE1 as a downstream effector of octanal/Olfr2 signaling in atherosclerosis, linking calcium-dependent ROS production with NLRP3 inflammasome-associated inflammation. The study combines mouse and macrophage models with pharmacological inhibition, RNA interference, and calcium chelation, providing a mechanistic framework for interpreting NHE1-centered protein and inflammatory assays.
-
Cisplatin, GSDME, and Gastric Cancer Pyroptosis
2026-09-29
The reference preprint identifies GSDME-associated pyroptosis as a mechanism through which Cisplatin (CDDP) kills gastric cancer cells. By combining transcriptomic profiling, bioinformatics, prognostic analysis, siRNA perturbation, RT-PCR, Western blotting, and cell-survival measurements, the study connects GSDME expression with Cisplatin sensitivity while also highlighting important limits for clinical translation.
-
EGCG Workflows for Bone and Cancer Research
2026-09-29
Translate (-)-Epigallocatechin gallate (EGCG) into reproducible cell, scaffold-release, vascularization, and tumor-cell workflows. The reference study shows how localized EGCG delivery from 3D-printed calcium phosphate can connect osteogenic, anti-osteoclastogenic, vascular, and chemopreventive readouts in one experimental platform.